Literature DB >> 27283410

Mechanisms of action and resistance for multiple myeloma novel drug treatments.

Shinsuke Iida1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27283410     DOI： 10.1007/s12185-016-2040-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  19 in total

1.  Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma.

Authors:  Chungyee Leung-Hagesteijn; Natalie Erdmann; Grace Cheung; Jonathan J Keats; A Keith Stewart; Donna E Reece; Kim Chan Chung; Rodger E Tiedemann
Journal:  Cancer Cell       Date:  2013-09-09       Impact factor: 31.743

2.  Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma.

Authors:  Teru Hideshima; James E Bradner; Jason Wong; Dharminder Chauhan; Paul Richardson; Stuart L Schreiber; Kenneth C Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-03       Impact factor: 11.205

Review 3.  Evolution of therapies for chronic myelogenous leukemia.

Authors:  Fabio P S Santos; Hagop Kantarjian; Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

4.  Identification of a primary target of thalidomide teratogenicity.

Authors:  Takumi Ito; Hideki Ando; Takayuki Suzuki; Toshihiko Ogura; Kentaro Hotta; Yoshimasa Imamura; Yuki Yamaguchi; Hiroshi Handa
Journal:  Science       Date:  2010-03-12       Impact factor: 47.728

Review 5.  Multistep tumorigenesis of multiple myeloma: its molecular delineation.

Authors:  Shinsuke Iida; Ryuzo Ueda
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

6.  Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Authors:  Jesús F San-Miguel; Vânia T M Hungria; Sung-Soo Yoon; Meral Beksac; Meletios Athanasios Dimopoulos; Ashraf Elghandour; Wieslaw Wiktor Jedrzejczak; Andreas Günther; Thanyaphong Na Nakorn; Noppadol Siritanaratkul; Paolo Corradini; Suporn Chuncharunee; Je-Jung Lee; Robert L Schlossman; Tatiana Shelekhova; Kwee Yong; Daryl Tan; Tontanai Numbenjapon; Jamie D Cavenagh; Jian Hou; Richard LeBlanc; Hareth Nahi; Lugui Qiu; Hans Salwender; Stefano Pulini; Philippe Moreau; Krzysztof Warzocha; Darrell White; Joan Bladé; WenMing Chen; Javier de la Rubia; Peter Gimsing; Sagar Lonial; Jonathan L Kaufman; Enrique M Ocio; Ljupco Veskovski; Sang Kyun Sohn; Ming-Chung Wang; Jae Hoon Lee; Hermann Einsele; Monika Sopala; Claudia Corrado; Bourras-Rezki Bengoudifa; Florence Binlich; Paul G Richardson
Journal:  Lancet Oncol       Date:  2014-09-18       Impact factor: 41.316

7.  Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Authors:  Meletios A Dimopoulos; Philippe Moreau; Antonio Palumbo; Douglas Joshua; Ludek Pour; Roman Hájek; Thierry Facon; Heinz Ludwig; Albert Oriol; Hartmut Goldschmidt; Laura Rosiñol; Jan Straub; Aleksandr Suvorov; Carla Araujo; Elena Rimashevskaya; Tomas Pika; Gianluca Gaidano; Katja Weisel; Vesselina Goranova-Marinova; Anthony Schwarer; Leonard Minuk; Tamás Masszi; Ievgenii Karamanesht; Massimo Offidani; Vania Hungria; Andrew Spencer; Robert Z Orlowski; Heidi H Gillenwater; Nehal Mohamed; Shibao Feng; Wee-Joo Chng
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

8.  Initial genome sequencing and analysis of multiple myeloma.

Authors:  Michael A Chapman; Michael S Lawrence; Jonathan J Keats; Kristian Cibulskis; Carrie Sougnez; Anna C Schinzel; Christina L Harview; Jean-Philippe Brunet; Gregory J Ahmann; Mazhar Adli; Kenneth C Anderson; Kristin G Ardlie; Daniel Auclair; Angela Baker; P Leif Bergsagel; Bradley E Bernstein; Yotam Drier; Rafael Fonseca; Stacey B Gabriel; Craig C Hofmeister; Sundar Jagannath; Andrzej J Jakubowiak; Amrita Krishnan; Joan Levy; Ted Liefeld; Sagar Lonial; Scott Mahan; Bunmi Mfuko; Stefano Monti; Louise M Perkins; Robb Onofrio; Trevor J Pugh; S Vincent Rajkumar; Alex H Ramos; David S Siegel; Andrey Sivachenko; A Keith Stewart; Suzanne Trudel; Ravi Vij; Douglas Voet; Wendy Winckler; Todd Zimmerman; John Carpten; Jeff Trent; William C Hahn; Levi A Garraway; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962

9.  Structure of the DDB1-CRBN E3 ubiquitin ligase in complex with thalidomide.

Authors:  Eric S Fischer; Kerstin Böhm; John R Lydeard; Haidi Yang; Michael B Stadler; Simone Cavadini; Jane Nagel; Fabrizio Serluca; Vincent Acker; Gondichatnahalli M Lingaraju; Ritesh B Tichkule; Michael Schebesta; William C Forrester; Markus Schirle; Ulrich Hassiepen; Johannes Ottl; Marc Hild; Rohan E J Beckwith; J Wade Harper; Jeremy L Jenkins; Nicolas H Thomä
Journal:  Nature       Date:  2014-07-16       Impact factor: 49.962

Review 10.  Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives.

Authors:  S Lonial; B Durie; A Palumbo; J San-Miguel
Journal:  Leukemia       Date:  2015-08-12       Impact factor: 11.528
View more
  5 in total

1.  Safety and efficacy of daratumumab in Japanese patients with relapsed or refractory multiple myeloma: a multicenter, phase 1, dose-escalation study.

Authors:  Shinsuke Iida; Kenshi Suzuki; Shigeru Kusumoto; Masaki Ri; Nobuhiro Tsukada; Yu Abe; Masayuki Aoki; Mitsuo Inagaki
Journal:  Int J Hematol       Date:  2017-06-22       Impact factor: 2.490

2.  In silico bioinformatics analysis for identification of differentially expressed genes and therapeutic drug molecules in Glucocorticoid-resistant Multiple myeloma.

Authors:  Somnath Ghosal; Subrata Banerjee
Journal:  Med Oncol       Date:  2022-02-12       Impact factor: 3.064

3.  Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum.

Authors:  Yayoi Matsumura-Kimoto; Junya Kuroda; Hitomi Kaneko; Yuri Kamitsuji; Shin-Ichi Fuchida; Aya Nakaya; Hirohiko Shibayama; Nobuhiko Uoshima; Isao Yokota; Hitoji Uchiyama; Hideo Yagi; Satoru Kosugi; Toshimitsu Matsui; Jun Ishikawa; Mitsuhiro Matsuda; Kensuke Ohta; Masato Iida; Hirokazu Tanaka; Masayuki Kobayashi; Katsuya Wada; Chihiro Shimazaki; Shosaku Nomura; Kazunori Imada; Masayuki Hino; Itaru Matsumura; Yuzuru Kanakura; Akifumi Takaori-Kondo
Journal:  Int J Hematol       Date:  2018-01-29       Impact factor: 2.490

4.  Chemometric and Transcriptomic Profiling, Microtubule Disruption and Cell Death Induction by Secalonic Acid in Tumor Cells.

Authors:  Nadire Özenver; Mona Dawood; Edmond Fleischer; Anette Klinger; Thomas Efferth
Journal:  Molecules       Date:  2020-07-15       Impact factor: 4.411

5.  Plasma enhance drug sensitivity to bortezomib by inhibition of cyp1a1 in myeloma cells.

Authors:  Dehui Xu; Qingjie Cui; Yujing Xu; Zeyu Chen; Wenjie Xia; Yanjie Yang; Dingxin Liu
Journal:  Transl Cancer Res       Date:  2019-12       Impact factor: 1.241
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.